Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance

Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($83.68); post-transaction worth based connected Feb. 6, 2026 marketplace adjacent ($83.68).

• How important was this merchantability comparative to Waddill’s humanities activity?
  This 20,000-share merchantability is 5 times larger than the caller median merchantability transaction of 4,000 shares.

• Was determination immoderate indirect information oregon usage of related entities?
  All transactions were conducted done nonstop ownership; nary indirect entities oregon trusts were involved, arsenic confirmed by post-trade holdings being zero for each indirect accounts.

• What marketplace discourse surrounded this transaction?
  The transaction coincided with a play of beardown terms performance, arsenic shares were priced astatine $83.68 (the marketplace closed astatine $84.49 connected Feb. 6, 2026), and the banal was up 123.8% implicit the anterior 12 months.

Protagonist Therapeutics is simply a clinical-stage biotechnology institution that uses proprietary peptide exertion to code unmet aesculapian needs successful hematology and immunology. It focuses connected patients with uncommon humor disorders and inflammatory diseases, partnering with healthcare providers and biopharmaceutical partners.

While Waddill’s merchantability of shares and exercising each of his remaining banal options with the institution does rise questions, it’s hard to pinpoint the nonstop crushed helium sold shares. However, what whitethorn beryllium notable for investors is that the bulk of Wall Street analysts complaint Protagonist Therapeutics’ banal a “strong buy,” and it has a precocious price-to-earnings ratio (P/E) of 113.15, which whitethorn bespeak precocious maturation expectations.

At the 44th yearly J.P. Morgan Healthcare Conference successful aboriginal January 2026, Protagonist highlighted its important projected maturation wrong the adjacent 12-24 months. The institution mentioned expanding its objective proceedings pipelines and that 2 cardinal pharmaceutical products person reached precocious stages of objective development, with backing from ample firms specified arsenic Johnson & Johnson.